These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
705 related articles for article (PubMed ID: 31142342)
1. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming. Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342 [TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway. Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834 [TBL] [Abstract][Full Text] [Related]
3. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma. Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651 [TBL] [Abstract][Full Text] [Related]
4. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816 [TBL] [Abstract][Full Text] [Related]
5. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Yang N; Chen T; Wang L; Liu R; Niu Y; Sun L; Yao B; Wang Y; Yang W; Liu Q; Tu K; Liu Z Theranostics; 2020; 10(13):5790-5801. PubMed ID: 32483419 [No Abstract] [Full Text] [Related]
6. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110 [TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 accelerates invasion by upregulating Snail in hepatocellular carcinoma cells. Zhang M; Zhang H; Cheng S; Zhang D; Xu Y; Bai X; Xia S; Zhang L; Ma J; Du M; Wang Y; Wang J; Chen M; Leng J Tumour Biol; 2014 Jul; 35(7):7135-45. PubMed ID: 24760275 [TBL] [Abstract][Full Text] [Related]
8. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. Lou G; Chen L; Xia C; Wang W; Qi J; Li A; Zhao L; Chen Z; Zheng M; Liu Y J Exp Clin Cancer Res; 2020 Jan; 39(1):4. PubMed ID: 31898515 [TBL] [Abstract][Full Text] [Related]
9. Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress. Zhang X; Li Y; Ma Y; Yang L; Wang T; Meng X; Zong Z; Sun X; Hua X; Li H J Exp Clin Cancer Res; 2018 Sep; 37(1):216. PubMed ID: 30180863 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition. Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919 [TBL] [Abstract][Full Text] [Related]
11. Hypoxia-induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway. Yao B; Li Y; Chen T; Niu Y; Wang Y; Yang Y; Wei X; Liu Q; Tu K Clin Transl Med; 2021 Mar; 11(3):e366. PubMed ID: 33784016 [TBL] [Abstract][Full Text] [Related]
12. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922 [TBL] [Abstract][Full Text] [Related]
13. Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap. Liu S; Miao R; Zhai M; Pang Q; Deng Y; Liu S; Qu K; Liu C; Zhang J Oncotarget; 2017 Jul; 8(29):47412-47424. PubMed ID: 28537892 [TBL] [Abstract][Full Text] [Related]
14. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141 [TBL] [Abstract][Full Text] [Related]
15. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN. Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis. Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820 [TBL] [Abstract][Full Text] [Related]
17. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways. Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231 [TBL] [Abstract][Full Text] [Related]
18. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858 [TBL] [Abstract][Full Text] [Related]
19. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma. Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295 [TBL] [Abstract][Full Text] [Related]
20. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Xu MZ; Chan SW; Liu AM; Wong KF; Fan ST; Chen J; Poon RT; Zender L; Lowe SW; Hong W; Luk JM Oncogene; 2011 Mar; 30(10):1229-40. PubMed ID: 21076472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]